Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.61M | $23.0M | 8.21% | +83.5K | 2026-03-31 |
| STATE STREET CORP | 4.51M | $13.0M | 4.87% | +128.6K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.86M | $11.0M | 4.17% | -- | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.19M | $6.0M | 2.36% | +165.4K | 2026-03-31 |
| CITADEL ADVISORS LLC | 1.17M | $3.0M | 1.26% | +128.9K | 2026-03-31 |
| Summit Financial, LLC | 940.5K | $2.0M | 1.01% | +37.1K | 2026-03-31 |
| BANK OF AMERICA CORP /DE/ | 863.1K | $2.0M | 0.93% | +339.0K | 2026-03-31 |
| GOLDMAN SACHS GROUP INC | 804.4K | $2.0M | 0.87% | -68.5K | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 783.1K | $2.0M | 0.85% | -- | 2026-03-31 |
| AQR CAPITAL MANAGEMENT LLC | 756.8K | $2.0M | 0.82% | +607.0K | 2026-03-31 |
